Allison Dorval: Thank you, Pat. Unless otherwise stated, all of my commentary regarding changes will be on a year-over-year basis. Pat already provided the revenue growth rate as there is added color, international OmniPod revenue represented 18% of our Q4 2014 revenue company's to 14% in Q3 3023. For the full year international OmniPod revenue represented 17% versus 10% in 2013. As Pat mentioned, our international partners continue to drive growth in 2014 and our international OmniPod revenues doubled. Consolidation gross profit increased 11% in the fourth quarter to $36.7 million. Gross margins were 51% reflecting approximately 60% margins on our US OmniPod business, offset by lower margins from our international OmniPod and neighborhood diabetes businesses. Gross profit for the full year of 2014 was $143.3 million, an increase of $30.9 million or 27%, and gross margins improved to 50% versus 45% last year. We continue to drive efficiencies with our manufacturing process and our focus is paid off, we experienced improved manufacturing throughout 2014 driving lowest entry [ph] cost and overall improvement in customer satisfaction. Q4 2014 operating expenses increased 19% to $38.9 million and included $3.8 million of charges related to the management team transition. There are no one-time charges in Q4 of last year. Operating expenses were $155.6 million for the full year of 2014 compared to $141.5 million in 2013. Operating expenses in 2014 including approximately $17.4 million of management transition and patent litigation settlement charges. Operating expenses in 2013 included approximately $10 million related to patent litigation settlement and next generation OmniPod launch cost. Net loss for the fourth quarter of 2014 was $5.4 million or $0.10 per share compared to $2.5 million or $0.04 per share in the prior year. The 2014 full year net loss was $51.5 million or $0.93 per share compared to $45.0 million or $0.83 per share in 2013. The main difference between our full year 2014 net loss and our $12.3 million operating loss was the $39.1 million of net interest expense which included the loss on extinguishment of our 3.75% convertible notes in addition to interest on our outstanding 2% convertible notes. Our cash balance was $151.2 million at the end of 2014 compared to $149.7 million at the end of 2013, and we had approximately 56.3 million shares outstanding. Turning to guidance, we expect full year 2015 revenue to be in the range of $305 million to $320 million representing a year-over-year increase of 6% to 11%. The majority of the growth is expected in the back half of the year as we gain traction from the new team and commercial initiative. We expect to see growth primarily within our US OmniPod business resulting from the renewed focus of the commercial team. We also expect to see solid growth within our drug delivery business, in fact we've previously stated that we anticipate $10 million to $20 million of revenue from this business and we now expect this range to be $15 million to $20 million. Lastly, 2015 revenue from both our international OmniPod and neighborhood diabetes businesses are expected to remain relatively consistent with prior year level. For the first quarter of 2015 we expect revenues of $67 million to $69 million, driven by a reduction of inventory levels by our international partners. This reduction will be partially offset by the expected increase in revenue from our drug delivery business. With that operator, please open the line for questions.
Allison Dorval: Part of it Mike is the timing that the patients are growing, so as you know we have discussed that, we added more new patients towards the back end of this year than we have it in the early part of this year. So that would account a portion of it.
Allison Dorval: Ben, in the past commentary if you talked about 5% of that neighborhood number incorporating OmniPod revenue, that's what the neighborhood businesses is selling on behalf of OmniPod.
Allison Dorval: So overall the relationship has been sell in, but GSK is purchasing inventory based on their demand, I'm sure that they will have some level of inventory in their warehouse on the date that we make that transition and I think as we finalize the agreement one week over the rest in Canada, there may be some repurchase of that inventory but it shouldn't be a take back of revenue by any means.
Allison Dorval: We talked about investing about $15 million or so in our commercial organization in 2015, I think that we need to get through 2015, see how the resources have come into play, make sure that they are being productive and then we'll talk about what we are planning to do in 2016 but I think at this point we're talking about 2015 and $15 million of additional spend over 2014.
Allison Dorval: I think as you're planning through the year I think we are anticipating getting to an operating breakeven level by Q4 of 2015.
Allison Dorval: Not really much different than what we were receiving under the J&J agreement - what we would have received under the J&J agreement.
Allison Dorval: No I don't think capacity was a big driver of 2014, I think in Q1 and Q2 we were able to bring our manufacturing lines back up to the levels that we needed them to be producing it, so I don't think it was the capacity.
Allison Dorval: I think for gross margin we talked about in the call that our US OmniPod sales are just over 60% gross margins, I think what you will see in 2015 is that any improvement in gross margin will largely be driven by mix, and we did mention that our international business as well as our neighborhood diabetes businesses are at lower gross margins, so as you bring in more US OmniPod sales, as you bring in more drug delivery, you will see some improvement in that gross margin level.
Allison Dorval: We haven't spoken out exactly how much was related to the international market, and unlike Pat said earlier, if that is ordering product again here in Q1, so we see the order volume getting back to where it should be and we expect by Q2 that will - that destocking will all be done.
Patrick Sullivan: I would start off by saying that the opportunity that I see to expand our OmniPod businesses is significant, we're only about 5% of the current type I diabetes patients and I think there is tremendous opportunity based upon the characteristics of the OmniPod system to significantly increase that. And I think with the appropriate focus on managing - marketing to the healthcare providers, as well as targeted marketing to the insurance companies we can knock down the obstacles that currently exist in getting OmniPod more widely adopted in the marketplace. I think fundamentally I've talked about this a lot that we fundamentally need to show the clinical benefit and the economic benefit to both, the doctors and the patients to provide widespread adoption for the product, we're focused on doing that with mining data sources that we have at the performance of the product in the field, as well as taking that information to the insurance plans which differentiates our product and show it's benefit to those - to the healthcare marketplace.
Patrick Sullivan: I think just to knock off the UNH issue, the issue that faced the company last year was paperwork issue and that issue with UNH has been resolved and we don't anticipate any further impact from that event that occurred last year. Let me frame the marketing effort, I think in order to really market any product you have to market - in our case, the three constituencies, we have to market to the healthcare providers, the doctors, in the office who prescribe the product; we have to market to the healthcare insurers who pay for the product; and finally we have to market to the patients who use the product. And in order to - we have to get all three of those moons in alignment to provide for widespread adoption. We have to market the features and benefits of our product and patients awareness for the patients know that this technology is available. We have to market the clinical and economic benefit to the doctors in the office so that they understand the benefit that this product has for their patients. And finally we have to market to the insurance carriers, the people that pay for it, the clinical and economic benefit for the people for whom they provide diabetes reimbursement, and I think it's - you have to get all those three moons in alignment to really provide the widespread adoption and I think historically the focus at Insulet has been on one moon, it's been mostly on the patients providing the tubeless technology in a convenience for the patients. And to a certain extent I think we really now need to change the focus to the healthcare providers who prescribe the product and the healthcare insurance companies that pay for it, and that hasnâ€™t been done historically.
Patrick Sullivan: We are shipping - we anticipate shipping to Ypsomed this quarter, we expect it to finish this quarter and back to normal ordering patterns - the quarterly ordering patterns in quarters two, three and four.
Patrick Sullivan: Well, obviously there has been more competitor activity but I'll come back to the tremendous opportunity and where we are getting the majority of our relative converting the MDI patients to OmniPod and quite frankly, we have not done a great job of differentiating the product to healthcare providers, to insurance plans, and we need to increase patient awareness as well. So I think with the opportunity for us, while we do worry about competition but I think our major competition is MDI quite frankly, and that's where we need to focus.
Patrick Sullivan: And the balance of it is just routine diabetes products such as testing and supplies, from supplies CGM, CGM supply etcetera, as well as the old service pharmacy.
Patrick Sullivan: I think we're going to continue to add new patients starts as we go throughout the year but the balance - more significant increase is going to be in the back half of the year as we get these marketing programs and sales force up to speed and fully productive in the field.
Patrick Sullivan: As I had mentioned, I think - I'm thoroughly confident the team will put in together, I mean if you think about it's not only sales and marketing, managed care marketing, it's - we, the whole commercial team have confidence that we're going to be able to increase the OmniPod revenue as we move forward with initial reporting in places just to get in and starts to have an effect.
Patrick Sullivan: No, I think itâ€™s Q2 is more, it's going to be more normalized and GSK is not as nearly as large component of our new international revenue, Ypsomed is.
Patrick Sullivan: I think what we're talking about increased utilization of that is all base is quite simply this, there are - although the vast majority of our patients or four times a year, there are those that don't order or less than four times a year, what we like to do is get all of our patients, order four times a year and we see that as an opportunity to increase utilization. And some of the reasons they don't order four times a year maybe that they - during the summer time or certain periods of the year they go back to MDI therapy and whatever reasons and in some cases the insurance coverage may change and they wonâ€™t any longer be - this happens in fact with Medicare, if a person is on OmniPod right now and they go on Medicare, since we don't have Medicare coverage they lose that current Medicare coverage and as you know Medicare doesn't currently reimburse for the OmniPod. So we're taking actions to try to get information to our patients that there are some important things for their health is to be on OmniPod 24/7/365, and secondly taking down the bury of Medicare reimbursement for the patients that are turning 65 and going on Medicare coverage. Those are the types of utilization initiatives I'm referring to.
Patrick Sullivan: No, I think in general as you all know pump therapy is reimbursed by insurance company. However, my point here is that insurance companies have certain requirements that patients must provide in order to have access to pump therapy or OmniPod and in some of those cases it's measurements of A1 fee [ph] over the period of time, glucose levels, other types of things that they need to do in order to be put on pump therapy. The way I think about this is, I can imagine a world where we have demonstrated the clinical and economic benefit to the insurance plans, that they would reduce those barriers to adopt to make more widely available insurance coverage for those patients, and in order to do you got to market for the insurance plans to show them your ability to change A1 fee levels for example and to provide other quality measurements that convinces them that reimbursing or having more people on pump therapy and OmniPod in particular is important for them. And so that's what I refer to when I talk about marketing to the insurance plans, it's because they make it sometimes difficult for patients to qualify or to be put on pump therapy because all of the hops they have to jump through. And secondly on Medicare coverage, we - as you know we don't have Medicare coverage and for patients over 65 that's an issue and something we're working on.
Patrick Sullivan: Yes, I would say it's probably around the 5% range of the neighborhoodâ€™s total revenues, 5% of that is OmniPod product that they are shipping to their patients or customers.
Patrick Sullivan: They are not, we don't - they would be not a big number. So we don't include those new patients, it's just to ease your poise, not to break that out at this point.
Patrick Sullivan: Based on our contract with Amgen we're not committed to provide any color on what they are doing. I can tell you that as Allison talked about early in the conference call we have taken the bow drug delivered estimate for the year up from $10 million to $15 million. So perhaps that's an indication of how it's going.
Patrick Sullivan: No, I think in order to provide continued and accelerated OmniPod growth we've got - as I mentioned, the aftermarket - we have more effective and targeted marketing to the healthcare providers and to the patients when we talked about focus on pediatric patient population. And I think continued demonstrating the clinical and the economic benefit to the payers. And I think as part of the product offering you always have to, in this market offer a service component that provides getting to patient from the doctor prescription onto the product and trend etcetera, and we are making some investments in our inside organization to improve the customer service experience or those patients that are not only coming on the product and ensuring that they have a very great patient experience in the first 90 days but for the existing customers, to reach out to them more frequently and communicate and really have a more comprehensive marketing program for our customers.
Patrick Sullivan: Yes, I would say our strategy is that as it relates to the artificial pancreas, we are putting together strategy so that OmniPod is a very significant part of the artificial pancreas product offering in the future. And with that you need to have a CGM product offering, as well as an offering to put the three units together if you will, and as you know we have been working internally on our own CGM development which continues but also we have an agreement with - already have an agreement with Dexcom to use their CGM sensor along with our new PDM to integrate that those two products together, and I think with that combination used in algorithm and we're looking at opportunities to have an algorithm that we could then provide the full package. I'd also say that we would evaluate and look at opportunities with Abbott and others that would have potential CGM integration opportunities for us. So in the short term we're looking at other people that have CGM capabilities and algorithm capability, but at the same time we are continuing at a low level our own efforts in our own CGM product development.
Patrick Sullivan: Well, first of all I'd like to thank you for your very complimentary remarks concerning the customer service. Our organization and your interaction within to it, as it relates to our OmniPod business, and then I'd also like to say we want to make that customer service experience even better for you, thank you. Secondly, I think you make a very good point where reference selling or having people that are currently on the product, refer it to their friends and physicians is a very important part of the overall strategy that we're developing through to get all three of the moons in alignment; the doctors, the patients, and the payers, so that we have broader adoption of the marketplace that more physicians are prescribing it and more healthcare/insurance companies are paying for it. So I think you were spot on, I'm going to pass that directly onto our marketing for its consideration and thank you for the great idea.
Patrick Sullivan: I think as it relates to clinical evidence I would use the term and in my remarks I didn't talk about new clinical studies, what I'm referring to is actually clinical data that's already available. There are many places throughout the country that we have a large base of OmniPod users and hopefully we're working to try to find a way to mind that database to show the clinical evidence of - for example, A1C levels on a person that was on MDI not going to OmniPod. So I think there is a fair bit of clinical data already out there that we simply need to mind, but as we go down the road it's getting more clinical trials and clinical evidence, we may need to look at - and incorporate doing some clinical trial work but that's not contemplated at this point, additional work is not contemplating at this point in time. And yes that is same information also it will be helpful with working for providers to serve the benefits of this - of the OmniPod as it relates to the performance for their patients.
Patrick Sullivan: I think - well, let me tell you where we are today, we have data on 59 patients that shows 0.59% reduction to me when sea levels. We have data in the field and available I think that we can mind - initial data shows that 1.1 reduction in A1C on little over a thousand patients. So that data is available - we'll get a statistical analysis and hope to use that in marketing to doctors and payers. The other thing I would mention is that, insurance plans are often evaluated by their customers, by big large employers on quality measurements related to the - measurements and those are quality measures that are used to - basically a report card for insurance plans and they specifically heated measures related to A1C levels and other measurements of diabetes care, and I think that's another avenue where if you can show an insurance plan that you can improve their A1C compliance, their A1C numbers, that's meaningful for them as they market to the large employers throughout the country. That's the kind of value proposition we need to bring to insurance companies that here before hasnâ€™t been done.
Patrick Sullivan: I think it's the - as you think of the benefits of the product, I mean there are many from product features that tubeless delivery among others, but I think the clinical benefit is that what are the A1C levels of individuals on MDI therapy before they go on the OmniPod and what are they have been on the OmniPod for a while, the data when you see consistently shows a reduction in A1C levels that are in our view significant. So I think that's the principal one is also in the data we've mined so far - 15 unit per day reduction in insulin usage. So I think there is a number of different metrics we can mind that's going to give us a dataset we can take the doctors and to payers.
Patrick Sullivan: We are definitely assuming improved representative productivity sales force effectiveness in the field. The team that I put together on the whole commercial side under our Chief Commercial Officer is - have all worked together, know how to drive sales forces, how to design sales forces, and to relate and try top line growth. So - absolutely we've got improvements in sales force productivity baked into our assumptions.
Patrick Sullivan: We expect the trial to begin this year and we have worked with delay on the protocol, both, what they are going to do, what we're going to do, and FDA has basically given us green light; it will start later this year, probably wonâ€™t be commercial until 2017.
Patrick Sullivan: Thank you very much. First of all I want to reiterate how excited I am to be at Insulet and how strongly I believe there are so many untapped opportunities before us. Our new senior leadership team is very well positioned to capitalize and provide improved commercial execution over a strong platform with our OmniPod system that will not only allow us to drive featured options with the right operating strategy in place, that will provide us with the unique and incredible opportunity to drive growth within the drug delivery business. I'm confident we are driving forward on the right strategy to position Insulet on long term accelerated growth and create shareholder value. I look forward to meeting many of you at Investor conferences over the coming months and keeping you updated on our progress on future calls, as well as providing you additional details about our execution, strategy and future vision. Thank you very much.
